C25 BioTelemetry Inc.

BioTelemetry, Inc. Names Dr. Andrei Stoica Chief Technology Officer

BioTelemetry, Inc. Names Dr. Andrei Stoica Chief Technology Officer

MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Dr. Andrei Stoica has been named Chief Technology Officer of the company.  Dr. Stoica will lead the company’s global technology and product development operations, reporting to Joseph H. Capper, President and Chief Executive Officer.

“We are delighted to welcome Andrei to our BioTelemetry team during this transformational time of growth and innovation,” said Joseph H. Capper, President and Chief Executive Officer of BioTelemetry.  “His extensive expertise in enterprise technology solutions, including cloud platforms, information security, and software and product development, will be instrumental as we continue to create best-in-class solutions across our product and service offerings.”   

Since 2006, Dr. Stoica held various leadership positions at IQVIA, most recently serving as its SVP, IT Systems Development, leading the development of the global data and AI/ML cloud platform.  His appointments prior to IQVIA include information technology positions in the health IT industry as well as research and teaching positions in academia.  Dr. Stoica holds a Ph.D. in Computer Science and Engineering from the University of South Carolina.  He has served on multiple committees and authored numerous papers, and has been recognized and awarded for his use of technology innovation to evolve enterprise IT.

“This is an exciting time for BioTelemetry, and I am looking forward to working with a team that shares my passion for leveraging technology and innovation to address today’s healthcare challenges and save lives,” said Dr. Stoica.  “BioTelemetry is an established leader in connected health, and we are uniquely positioned to offer a continuum of solutions that truly makes a difference for our patients and customers.  Our IoT cloud platform and clinical subject matter expertise already provides a differentiating capability to aid physicians in making informed decisions about patient treatments, and our platforms will constantly improve powered by AI/ML technologies.”

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core lab services for clinical trials, remote blood glucose monitoring, and original equipment manufacturing that serves both healthcare and clinical research customers.  More information can be found at .

Contact:    BioTelemetry, Inc.
  Heather C. Getz
  Investor Relations
  Executive Vice President, Chief Financial Officer
  800-908-7103
  
   
  BioTelemetry, Inc.
  Amy M. Knapp
  Media Relations
  Vice President, Corporate Communications
  813-277-8456
  

EN
07/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioTelemetry Inc.

 PRESS RELEASE

Philips to Acquire BioTelemetry

Philips to Acquire BioTelemetry Philips to acquire BioTelemetry, Inc. for USD 72.00 per share; implied enterprise value of USD 2.8 billion (approx. EUR 2.3 billion)Acquisition is a strong fit with Philips’ strategy to transform the delivery of healthcare: combination of Philips’ leading patient monitoring position in the hospital with BioTelemetry’s leading cardiac diagnostics and monitoring position outside the hospitalWith 2019 sales of USD 439 million, BioTelemetry annually monitors over 1 million cardiac patients remotely; its portfolio includes wearable heart monitors, AI-based data an...

 PRESS RELEASE

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results Posts Record Quarterly Revenue Amidst Rapid Recovery MALVERN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended September 30, 2020. Quarter Highlights Recognized quarterly total revenue of $114.7 millionReached 3.0% year-over-year quarterly revenue growth, despite the impact of COVID-19Reported quarterly GAAP net...

MarketLine Department
  • MarketLine Department

CardioComm Solutions, Inc. - Mergers & Acquisitions (M&A), Partnership...

Summary Marketline's CardioComm Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by CardioComm Solutions, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdow...

 PRESS RELEASE

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on O...

BioTelemetry, Inc. to Release Third Quarter 2020 Earnings Results on October 29, 2020 MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on Thursday, October 29 at 4:00 PM Eastern Time. BioTelemetry, Inc. will host an earnings conference call on Thursday, October 29, at 5:00 PM Eastern Time.  The call will be webcast on the investor information page of our website, .  The call will be archived on our website for at least two weeks. About BioTelemetryBioTelemetry, Inc. is the leading remote medical technology comp...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch